Close
What is CPIC?

The Clinical Pharmacogenetics Implementation Consortium (CPIC®) is an international consortium of individual volunteers and a small dedicated staff who are interested in facilitating use of pharmacogenetic tests for patient care.

One barrier to implementation of pharmacogenetic testing in the clinic is the difficulty in translating genetic laboratory test results into actionable prescribing decisions for affected drugs.

CPIC’s goal is to address this barrier to clinical implementation of pharmacogenetic tests by creating, curating, and posting freely available, peer-reviewed, evidence-based, updatable, and detailed gene/drug clinical practice guidelines (click here for all CPIC publications).  CPIC guidelines follow standardized formats, include systematic grading of evidence and clinical recommendations, use standardized terminology, are peer-reviewed, and are published in a leading journal (in partnership with Clinical Pharmacology and Therapeutics) with simultaneous posting to cpicpgx.org, where they are regularly updated.

CPIC started as a shared project between PharmGKB and the Pharmacogenomics Research Network (PGRN) in 2009. CPIC guidelines are available on guidelines.gov, indexed in PubMed as clinical guidelines, endorsed by ASHP and ASCPT, and referenced in ClinGen and PharmGKB.

Team

Leader
Mary V. Relling, Pharm.D.
St. Jude Children’s Research Hospital, Memphis

Leader
Teri E. Klein, Ph.D.
Stanford University

Director
Kelly Caudle, Pharm.D., Ph.D.
St. Jude Children’s Research Hospital, Memphis

Steering Committee

Mary V. Relling, Pharm.D. St. Jude Children’s Research Hospital, Memphis

Teri E. Klein, Ph.D. Stanford University

Julie A. Johnson, Pharm.D. University of Florida

Dan M. Roden, M.D. Vanderbilt University

Rachel F. Tyndale, Ph.D. University of Toronto and CAMH

Scientific Advisory Board

Gwendolyn A. McMillin, Ph.D. ARUP Laboratories

Robert Nussbaum, M.D. University of California, San Francisco

Heidi Rehm, Ph.D. Partners Healthcare

Marc S. Williams, M.D. Geisinger

Brad Strock, Epic

Sandy Aronson, Partners Personalized Medicine

  • CPIC Guideline Update: Carbamazepine, Oxcarbazepine and HLA genotype February 14, 2018
    The CPIC Guideline for carbamazepine, oxcarbazepine and HLA genotype is now published in Clinical Pharmacology and Therapeutics. The accepted article can be viewed on the PharmGKB pages for carbamazepine and oxcarbazepine and on the CPIC website. Carbamazepine and oxcarbazepine are anticonvulsants which have been approved for treatment for epilepsy and, in the case of carbamazepine, trigeminal neuralgia. Patients with the HLA-A*31:01 and/or the […]
  • New CPIC Guideline: CYP2D6 and tamoxifen January 31, 2018
    The CPIC Guideline for tamoxifen and CYP2D6 is now published in Clinical Pharmacology and Therapeutics. The accepted article can be viewed on the PharmGKB page for tamoxifen, and the CPIC website. Tamoxifen is a selective estrogen receptor modulator (SERM) and is utilized in breast cancer treatment. Tamoxifen is extensively metabolized, in part by CYP2D6. Patients with certain CYP2D6 genetic polymorphisms and […]
  • PharmCAT commentary in Clinical Pharmacology & Therapeutics December 1, 2017
    A commentary about the Pharmacogenomics Clinical Annotation Tool (PharmCAT) was recently published in Clinical Pharmacology & Therapeutics.  PharmCAT is developed in a collaboration between the former PGRN Statistical Analysis Resource (P-STAR) and the Pharmacogenomics Knowledgebase (PharmGKB) with input from other groups (click here for a list of participants). PharmCAT will extract PGx variants, beginning with variants […]
  • CPIC Guideline Update: DPYD and Fluoropyrimidines November 21, 2017
    The 2017 update of the CPIC Guideline for Fluoropyrimidines and DPYD is now available as an advance online publication in Clinical Pharmacology and Therapeutics. CPIC extensively reviewed the literature up to March 2017. Both the dosing recommendations and supplemental information were updated. The accepted article can currently be viewed on the PharmGKB pages for capecitabine and fluorouracil, and the CPIC website. Fluoropyrimidines are mainly used to treat solid […]
  • Curators' Favorite Papers September 28, 2017
    For this month's edition of "Curators' Favorite Papers" we present two articles discussing how the recommendations from Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines have been used at two different healthcare settings.Implementation of Clinical Pharmacogenomics within a Large Health System: From Electronic Health Record Decision Support to Consultation Services by Sissung et al. discusses the experience of […]